BioArctic AB Series B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB Series B (0RV2) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2021: -0.050x
Based on the latest financial reports, BioArctic AB Series B (0RV2) has a cash flow conversion efficiency ratio of -0.050x as of December 2021.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-39.25 Million) by net assets (Skr788.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioArctic AB Series B - Cash Flow Conversion Efficiency Trend (2017–2021)
This chart illustrates how BioArctic AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioArctic AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioArctic AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Changhong Tech
SHE:300151
|
0.045x |
|
Adaro Minerals Indonesia Tbk PT
JK:ADMR
|
0.074x |
|
Fengzhushou Co. Ltd. A
SHE:301382
|
N/A |
|
S N Nuclearele
RO:SNN
|
0.054x |
|
Whitestone REIT
NYSE:WSR
|
0.079x |
|
CGN Mining Company Limited
PINK:CGNMF
|
-0.042x |
|
Beijing Lier High Temperature Materials Co Ltd
SHE:002392
|
0.010x |
|
Baosheng
SHG:600973
|
0.072x |
Annual Cash Flow Conversion Efficiency for BioArctic AB Series B (2017–2021)
The table below shows the annual cash flow conversion efficiency of BioArctic AB Series B from 2017 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-12-31 | Skr788.68 Million | Skr-140.46 Million | -0.178x | -74.98% |
| 2020-12-31 | Skr907.30 Million | Skr-92.34 Million | -0.102x | -130.32% |
| 2019-12-31 | Skr974.50 Million | Skr327.17 Million | 0.336x | +270.79% |
| 2018-12-31 | Skr1.02 Billion | Skr-200.06 Million | -0.197x | +7.60% |
| 2017-12-31 | Skr636.13 Million | Skr-135.33 Million | -0.213x | -- |